NCT07536048 2026-04-17
A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
Sanofi
Not yet recruiting
Clinical Trials
10 trialsNCT07368153 2026-01-26
IDEP
University Hospital, Basel, Switzerland
Phase 2 Not yet recruiting
NCT07261215 2025-12-03
Zuberitamab for EBV Infection Post-Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07138989 2025-08-24
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07133776 2025-08-21
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
The Affiliated Hospital of Xuzhou Medical University
Phase 1/2 Not yet recruiting
NCT05688241 2025-03-03
ESPECT
University Hospital, Basel, Switzerland
Phase 1/2 Not yet recruiting
NCT06480903 2024-06-28
ClearED
The Christie NHS Foundation Trust
Not yet recruiting
NCT06426758 2024-05-23
Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
Nanjing Medical University
Not yet recruiting
NCT06131489 2023-11-14
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
Beijing Friendship Hospital
Not yet recruiting
NCT05775705 2023-03-20
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital
Phase 3 Not yet recruiting